Skip to main content

NEW YORK (TheStreet) -- Shares of Hyperion Therapeutics (HPTX) rose 8% this morning after the company announced that it had agreed to be acquired for $46 per share by Horizon Pharma (HZNP) - Get Horizon Therapeutics Public Limited Company Report. Hyperion shares closed at $42.74 on Friday. In a note to investors on February 27, research firm Brean Capital called the company a potential takeover target. The Fly published a summary of Brean's note on that day. Hyperion is a drug maker than focuses on orphan diseases and hepatology.

WHAT HAPPENED: On February 27, following Hyperion's fourth quarter results, Brean Capital analyst Difei Yang wrote that, given Hyperion's attractive valuation, the company could be a takeover target. Despite the fact that Hyperion is a profitable drug company, the stock "stubbornly underperformed" the shares of similar companies, according to Yang, who reiterated a $40 price target and Buy rating on the shares at that time.

PRICE ACTION: In late morning trading, Hyperion jumped $3.38, or 7.9%, to $46.11. On February 27, the date of Brean's note in focus, Hyperion shares closed at $29.55. Meanwhile, shares of the buyer, Horizon Pharma, are up 15% to $25.18 this morning.

Reporting by Larry Ramer.

TheStreet Recommends

The Fly

is a leading digital publisher of real-time financial news. Our financial market experts understand that news impacting stock prices can originate from anywhere, at anytime. The Fly team scours all sources of company news, from mainstream to cutting-edge, then filters out the noise to deliver short-form stories consisting of only market moving content. Follow @theflynews on Twitter. For a free trial, click